Opendata, web and dolomites

URO-BEST

UROthelial carcinoma Biomarker based diagnostic tEST

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 URO-BEST project word cloud

Explore the words cloud of the URO-BEST project. It provides you a very rough idea of what is the project "URO-BEST" about.

initial    launch    bta    believe    standard    biotech    cancer    diagnostic    presenting    frequent    figures    vs    gt       12    usa    invention    requiring    81    global    first    transurethral    billion    perfom    secure    biomarker    fina    controls    ongoing    urovysion    40    demonstrating    200million    rates    gold    performance    providers    monitor    patient    1st    clinically    differentially    opportunity    hence    near    patent    surveillance    survival    discriminating    filed    sensitivity    94    validated    diagnosed    malignancies    stat    costliest    superior    protecting    period    genes    assay    patients    525    nmp22    licensing    specificity    invasive    380    molecular    validate    healhty    70    unmet    costly    13    detected    tool    cystoscopy    combined    multicenter    pct    exists    91    expressed    japan    genetic    samples    60    worldwide    complications    yearly    urine    cancers    market    relapse    cytology    uro    tests    million    cystoscopies    healthcare    2013    operate    freedom    urologists    international    bladder    reduce    averaging    signatures    risk    treat    diagnosis    estimate   

Project "URO-BEST" data sheet

The following table provides information about the project.

Coordinator
FINA BIOTECH S.L. 

Organization address
address: CAMINO DE LAS HUERTAS 2, EDIFICIO 1
city: POZUELO DE ALARCON
postcode: 28223
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.finabiotech.es/investigation/diagnostics/dx-bladder-cancer/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FINA BIOTECH S.L. ES (POZUELO DE ALARCON) coordinator 50˙000.00

Map

 Project objective

Bladder cancer is among the five most common malignancies worldwide: more than 380.000 new cases are diagnosed yearly. If detected early, 5-year survival is high (94%),but >70% of diagnosed patients will relapse within this period. The current gold standard diagnostic tool is combined cytology and cystoscopy which is costly and highly invasive requiring transurethral access and presenting the risk of important complications. Due to high relapse rates, surveillance requires frequent cystoscopies, averaging 13 controls per patient after initial diagnosis. Hence, bladder cancer is one of the costliest cancers to treat and monitor. Only in the USA, Europe and Japan, more than 4.5 million cystoscopies are conducted yearly, 40% for 1st diagnosis and 60% for surveillance, at a cost near to $2 billion to healthcare providers. Urologists believe that an opportunity exists to reduce the number of SURVEILLANCE cystoscopies with a reliable, cost-effective, robust, easy-to-perfom and non-invasive assay. URO-BEST addresses this unmet need. Based on signatures of 2, 5,10 and 12 differentially-expressed genes, this test has been clinically validated in a multicenter international study on 525 urine samples demonstrating 81% sensitivity and 91% specificity in discriminating cases vs. healhty patients for first diagnosis, figures comparable to that of the gold standard and superior to other existing molecular diagnostic products (Urovysion, NMP22, BTA Stat). We estimate the current market for bladder cancer biomarker based tests at greater than > $200million. Fina Biotech has filed European and PCT patent applications protecting the invention in 2013. Fina Biotech aims to clinically validate the diagnostic performance of the genetic signatures in patients under SURVEILLANCE for its launch to the market: advance ongoing discussions with potential partners for global licensing,increase urologists awareness and secure freedom to operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "URO-BEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "URO-BEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More